Vergelijking
Semaglutid vs. Survodutide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
910463-68-2
2179963-22-7
Molecuulmassa
4113.6 g/mol
4727 g/mol
Halfwaardetijd
165 h
168 h
Sequentie
modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-Linkermodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteWerkingsmechanisme
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
4
4
waarvan bij mensen
3
4
Geregistreerde effecten
3
3
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
5
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Semaglutid and Survodutide?
- Semaglutid is classified as "Metabool", while Survodutide is classified as "Metabool". Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Semaglutid or Survodutide?
- The highest available evidence level is "Humane RCT" for Semaglutid and "Humane RCT" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Semaglutid and Survodutide in Germany and the United States?
- Duitsland: Semaglutid — Op recept, Survodutide — Niet goedgekeurd. Verenigde Staten: Semaglutid — Op recept, Survodutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.